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Hemodialysis Vascular Access with 
Central Venous Disease
Hemant J. Mehta
Abstract
Vascular access (VA) for hemodialysis (HD) is the lifeline of a patient. 
Arteriovenous fistula (AVF) is the gold standard of VA, but there are challenging 
situations when providing long-term VA becomes challenging, in the presence of 
central vein stenosis (CVS), which is common in patients on hemodialysis, but its 
exact prevalence is not known. It would be ideal to have proper venous mapping 
with imaging modality to be able to plan central venous access. This prior venous 
mapping will help to plan the target vein and delineate venous path to be able to 
place HD catheter in the best position or resolve the VA-related problems. However, 
digital subtraction angiography remains the gold standard of the procedure, during 
which the target vein is accessed via ultrasound guidance, and subsequent passage 
of wire is done under fluoroscopic guidance. Venous angiography and, if indicated, 
angioplasty are performed. For complete chronically occluded thrombotic veins, 
recanalization needs to be attempted. Stenting is reserved for a select group of 
patients. There are advances in endovascular techniques to deal with CVS, and it 
needs a multidisciplinary team approach to tackle the complex issues of VA-related 
central venous disease (CVD).
Keywords: hemodialysis vascular access, central venous disease, central venous 
stenosis, central vein angioplasty, central vein stenting, complete thrombotic 
occlusion of central veins
1. Introduction
Long-term hemodialysis (HD) is dependent on reliable vascular access (VA), 
which is the lifeline of a patient. We have come a long way in the chronic HD 
treatment due to advances in VA. Starting from Scribbner’s shunt to single-lumen 
HD catheters in the femoral vessels to double-lumen non-tunneled non-cuff HD 
catheters, to tunneled cuff catheters (TCC), and to early stick arteriovenous grafts; 
all for urgent start HD. Over the years, we also moved the catheters from subclavian 
veins (SCV) to internal jugular veins (IJV), for VA in the upper part of the body, 
basically for access draining to the superior vena cava (SVC). Unfortunately, the 
non-cuffed HD catheters became a tool to continue HD for a prolonged period 
(a practice very commonly encountered in the part of the world where the author is 
working, mainly due to nonavailability of VA expertise) in the absence of matured 
arteriovenous fistula (AVF) or graft. This led to injury to the vessel wall, leading to 
thrombosis and central vein occlusion and compromised VA for HD due to central 
venous stenosis (CVS). Even the TCCs are associated with CVS. Two major factors 
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implicated in development of CVS are venous trauma resulting from cannulation of 
central veins and hemodynamic stress secondary to high flow due to access site AVF, 
causing central venous disease (CVD).
AVF is the gold standard of VA. Ideally, all patients starting HD should have 
AVF in place, but that is not possible. In 2015, 80% of patients were using a cath-
eter at HD initiation, a rate that has changed only marginally since 2005, and at 
90 days after the initiation of HD, 68.5% of patients were still using catheters [1, 2]. 
Late referral by nephrologists to surgeons has been an underappreciated cause of 
initiation of HD with central catheters. [3]. There are situations when a patient has 
multiple AVF failures, in the upper limbs. It then becomes a challenging situation to 
provide dialysis to these patients with a reliable access. The problem is further com-
pounded in patients with prior central vein HD catheters, resulting in CVD. CVS 
is considered to be common in patients on hemodialysis, but its exact prevalence 
is not known. The CVS may have occurred due to insertion of central catheters, 
PICC, or pacemaker leads. Due to direct contact of these devices with the wall of 
the central veins, and the constant movement, both lateral (like a pendulum) and 
cephalocaudal direction associated with breathing and the cardiac cycle cause 
endothelial injury. Pathological examinations of central veins obtained at autopsy 
have shown that even short-term catheters are associated with foci of local intimal 
injury with endothelial denudation and adherent thrombus [4].
In patients with AVF, development of CVS is partly related to turbulent blood 
flow and neointimal hyperplasia (NIH). Infection related to prior catheter insertion 
may also be responsible for CVS. Extrinsic compression, either musculoskeletal or 
arterial, can be contributing to CVS.
However, in an otherwise healthy person, the CVS hardly, if ever, causes prob-
lems. The problem comes to light when an AVF or graft is placed on the ipsilateral 
side where there is presence of CVS. It also gets recognized when a fresh attempt is 
made to insert cuffed or non-cuffed tunnel catheter in the central vein. We should 
realize that CVS leading to CVD is difficult to treat and often resistant to treat-
ment. In CVD, VA for HD sometimes need to be abandoned, or in serious cases, the 
patient’s life may be threatened. Therefore, one should strive for the ideal situation 
of catheter avoidance and central vein preservation and remember that prevention 
is ideal and better than cure.
2. Clinical case study
This is a 52-year-old diabetic female, who was on regular hemodialysis 3 times a 
week with right internal jugular vein (IJV) TCC as her vascular access for 7 months 
and a non-maturing left brachiocephalic vein AVF. She presented with progres-
sively increasing orthopnea of 1-week duration and was presumed to have coronary 
artery disease. She was referred to our hospital cardiology department for coronary 
angiography (CAG), who subsequently asked nephrology services to give her a 
post CAG dialysis. Her CAG was normal. When on dialysis and on attempting to 
ultrafilter her, she had intradialytic hypotension, with persistent and increasing 
breathlessness. She was examined by a consultant and a clinical diagnosis of CVS 
was made. The patient was clinically not in fluid overload state. HD was terminated, 
and her blood pressure and symptoms settled. The next day, she underwent con-
trast-enhanced tomography of central vein, which proved stenosis at the cavo-atrial 
junction, at the site of the tip of the dialysis catheter. She was subjected to central 
vein angioplasty and her symptoms resolved (Figure 1) (author’s personal work).
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3. What are central veins?
In the neck, SVC, bilateral brachiocephalic vein (BCV), IJV, external jugular vein 
(EJV), and SCVs would constitute the central veins for upper limb access, whereas 
femoral, common iliac, and external iliac veins and the infrarenal inferior vena cava 
could constitute the lower limb central veins.
Figure 1. 
CT scan and angiography images: (a) 3D reconstructed image showing clots around the TCC tip and also 
multiple collateral veins in the thoracic cage, suggestive of CTO; (b) stenosis at cavo-atrial junction at the site 
of TCC tip; (c) findings of (b) on CT scan are confirmed on angiography; and (d) angioplasty of the CVS with 
TCC in situ.
Cardiac Diseases
4
4. Preservation of central veins
Since CVS precludes to a creation of successful VA for long-term HD, it is 
essential to spread the awareness about preservation of central veins. It is a common 
practice to preserve peripheral veins (especially in nondominant hand) in a patient 
with chronic kidney disease (CKD, G III or higher). This is known to residents, 
fellows, nursing staff, etc. However, the concept of preservation of central veins in 
CKD is not widespread. CKD patients do get repeated central catheters at pre-HD 
stage due to medical problems, or PICC line, or the cardiologists requiring to put 
cardiac rhythm devices. There needs to be a dialog with cardiology colleagues to 
try and avoid insertion of SCV leads in CKD patients who are going to need HD 
in future. They can be requested to go for epicardial lead pacemakers (Figure 2) 
(author’s personal work). Also, stiff non-cuffed HD catheters should not be kept in 
situ in jugular veins for more than 15 days. Even if patient has acute kidney injury 
and likely to need prolonged HD beyond 15 days, it is essential to change them to 
TCC, which has lesser chances of CVS than non-cuffed catheters. SCV catheteriza-
tion should not be performed in CKD patients, although it still occurs frequently. 
Many intensivists prefer SCVs for central line insertion, and they should be con-
vinced to avoid it in CKD patients.
5. Pathophysiology
CVS can be either related or unrelated to current or previous catheters. Catheter-
associated CVS are related to type of catheter, i.e., stiff non-tunneled or softer 
tunneled catheter, duration, number of catheters in the same site, vein site, and tip 
position are all related to CVS. The material of catheter can be responsible for plate-
let aggregation and thrombosis. This can lead to episodes of catheter-related blood-
stream infections (CRBSI). Also, the blood turbulence produced due to tip design 
can be responsible for CVS. Traditionally, catheters inserted in SCVs are known to 
cause CVS, as the SCV is located between the clavicle and first rib. However, left IJV 
or EJV catheters passing through the left brachiocephalic veins are responsible for 
left BCV stenosis. In the left BCV, stenosis occurs at two points, at the junction of the 
Figure 2. 
(A) Pacemaker lead, with TCC. Pull back angiograph shows SVC occlusion and filling of azygous vein. (B) 
Pacemaker with epicardial leads in a patient with CKD GIIIb due to DKD.
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left IJV to the left SCV and junction of the left BCV to the right BCV continuing as 
the SVC. So, the stenosis occurs at the contact points of catheters with vessel wall in 
this situation. Also, left BCV is situated between aorta and sternum and can con-
tribute to stenosis. Right IJV catheters were not considered to cause CVS; however, 
prolong catheters in the right IJV, passing through the right BCV, can also cause right 
BCV CVS. Catheter tips in the SVC or SVC-right atrium junction are also known to 
cause thrombosis and/or CVS at the tip position site, (as illustrated in the clinical 
case above). Catheters on the ipsilateral side of cardiac rhythm device lines or ipsi-
lateral AVF are also known to cause CVS. In the later situation, it is due to turbulent 
blood flow at high flow generated by AVF. This is more prominently seen in cephalic 
arch with proximal brachiocephalic AVF and rarely with distal radio-cephalic AVF.
6. Asymptomatic CVS
Patients with prior history of central catheters or pacemaker leads may have CVS 
but are usually asymptomatic. The CVS comes to notice only when a VA is placed on 
ipsilateral side of CVS or a patient undergoes imaging for some other indications. 
Even in the presence of VA, asymptomatic CVS (<50%) are sometimes detected 
during other radiological procedures. These are usually found in cephalic arch or 
brachiocephalic veins. If these lesions are asymptomatic, one need not do interven-
tion, even if stenosis is >50%. These require only observation for development of 
any symptoms or signs. This is because central veins are more elastic and prone 
to recoil after angioplasty. Also, the intimal damage to the veins caused by angio-
plasty balloon (cracking and fissuring of the vessel intima) may accelerate further 
stenosis, due to aggregation of thrombocytes and occurrence of thrombi leading to 
intimal hyperplasia and fibrosis at the site of the original stenosis [5, 6].
Prophylactic treatment of a stenosis that fulfills the anatomic criteria (>50% 
diameter reduction) but is not associated with a hemodynamic, functional, or clini-
cal abnormality is not warranted and should not be performed. This is especially 
important for central venous lesions [7]. Two studies in one cohort were performed 
to address the issue of likelihood of developing CVS. Among 2811 patients, central 
venous stenosis was diagnosed in 120 (4.3%), at a median dialysis vintage of 2.9 
(interquartile range, 1.8–4.6) years. Among a subset of 500 patients, all with a his-
tory of catheter use, 34 (6.8%) developed central venous stenosis, at a rate of 2.2 per 
100 patient-years. The incidence of central venous stenosis was higher with a larger 
number of previous catheters [relative risk (RR), 2.2; 95% confidence interval (95% 
CI), 1.6–2.9]and pacemaker insertion (RR, 3.9; 95% CI, 1.7–8.9) and was lower with 
older age (RR, 0.7 per decade; 95% CI, 0.6–0.8) [8].
7. Diagnosis of CVS in symptomatic patients
The diagnosis of CVS is made from clinical and imaging findings. Most patients 
will have a history of previous central venous catheter placement and will pres-
ent with ipsilateral arm, breast, face, or neck swelling. Many patients will have 
evidence of AV access dysfunction, with decreased access flows, increased venous 
pressures during dialysis, and a history of excessive bleeding from the puncture 
site after removal of needle. CVS leading to venous hypertension (VH) in the 
ipsilateral extremity and chest wall is a frequently encountered problem affecting 
17 to 40% patients on HD. On physical examination, there may be numerous dilated 
collaterals in the neck or chest and arm edema or dilated tortuous draining veins 
of fistula on the side of the CVS. In the cases of bilateral innominate vein or SVC 
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stenosis or occlusion, patients may present with SVC syndrome. CVS can often be 
diagnosed by duplex ultrasound, with an absence of normal respiratory variation in 
the diameter of central veins and polyphasic atrial waves. It is difficult to visualize 
the central veins with duplex ultrasound in obese and muscular patients [9]. The 
author has seen patients with severe CVS presenting with not only ipsilateral limb 
edema but hemifacial swelling, diminished vision, and hearing loss on the right side 
and throbbing headache. We have also encountered a patient in whom there was 
no prior history of any catheters or lines but had narrowed fibrosed right IJV. This 
was detected at the time of insertion of TCC for initiation of chronic dialysis. In 
this particular patient, right EJV was patent (indirect evidence that the right IJV 
was blocked for a long time, but patient was asymptomatic). We had a patient with 
right upper limb oedema and history of multiple right IJV non-cuffed catheters 
for dialysis but never had any SCV catheters. During angiography, right SCV was 
found to be thrombosed. As per the European Best Practice Guidelines on VA [10], 
if symptomatic CVS is suspected, digital subtraction angiography (DSA) of the 
access and the complete venous outflow tract should be performed. In certain cases, 
ultrasonography with Doppler, computerized tomography (CT) of central veins or 
magnetic resonance imaging (MRI) plain study with time of flight (TOF) technique 
(Figure 3) may be deployed prior to DSA for venous mapping.
The main regions of central vein which are affected are the right BCV or SCV, 
right IJV, left BCV or SCV, and left IJV or SVC. The problem of cephalic arch 
stenosis in proximal brachiocephalic AVF (prevalence ~30%) or sometimes due to 
radio-cephalic AVF should also be kept in mind. Percutaneous transluminal angio-
plasty (PTA) with balloon dilatation is the primary basis for endovascular therapy. 
However, balloon dilation should be performed only if there is a clinical indication 
such as arm or face swelling. Several studies have reported that balloon dilation for 
a narrowed lesion found incidentally on angiogram and without symptoms acceler-
ates lesion growth [11–13].
Figure 3. 
MRI using TOF protocol, without contrast, to have venous mapping prior to intervention, in a patient who 
was grossly edematous and had no veins available to perform CT venography. It showed multiple levels of CVS, 
including bilateral IJVs, EJVs, and bilateral BCVs.
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A major problem with lesions in the central veins is that many are elastic. It 
has been postulated that there are actually two types of lesions based upon their 
response to angioplasty, elastic and inelastic [14].
It is reasonable to perform PTA for central venous lesion if this intervention is 
required to maintain stable dialysis therapy. However, the presence of large fresh 
thrombus at the lesion site represents a contraindication to PTA unless the throm-
bus can first be removed by thrombectomy or another method. The left brachioce-
phalic lesions can be due to not only compressive stenosis but also organic stenosis. 
In particular, the left brachiocephalic vein may be compressed between the sternum 
and the right brachiocephalic artery [15].
8. CVD and similar conditions
The lesions can be partial but significant (>60% stenosis, for intervention 
purpose, however, venography demonstrating more than 50% stenosis of the sub-
clavian, brachiocephalic vein, and superior vena cava in the upper extremity or the 
iliac vein or inferior vena cava in the lower extremity is considered central venous 
occlusion) or complete thrombotic occlusion [or chronic total occlusion (CTO)]. 
In addition, patients with TCC present with catheter malfunction and may have 
catheter-related sheath (CRS) (old term: fibrin sheath), with or without clot at the 
catheter tip (called catheter-related atrial thrombus, CRAT).
9. Options for patients with CVS needing VA
They can change to peritoneal dialysis if feasible. One can plan for thigh AVF or 
graft. But if both these are not the options, one is left with exploring central venous 
access with angioplasty and insertion of HD catheters, with TCC or Hemodialysis 
Reliable Outflow (HeRO®) device. For the purpose of this chapter, we would focus 
on upper limb CVS. Not to forget the fact that in the presence of SVC stenosis, no 
AVF or upper limb grafts will be feasible if the SVC stenosis is tight and has a chance 
for recurrence in spite of SVC angioplasty with or without stent. With improved 
dialysis survival, there are increasing numbers of patients who have exhausted 
definitive access options due to central venous stenosis and are maintaining dialysis 
on a central venous catheter. The HeRO allows an alternative by providing a defini-
tive access solution [16].
10. The procedure: approaching and crossing stenosis
The approach to central vein could be from femoral veins, internal jugular 
veins, and brachial or cephalic veins. One needs to have thorough history, clinical 
examination, and Doppler study to arrive at a conclusion about suspected site of 
CVS. When these are unable to point the site of likely lesion, one may perform 
contrast-enhanced computer tomography (CT) venogram. The problem with CT 
venography is the need to inject iodinated contrast. This can be a problem in HD 
patients at times, who have no peripheral access to inject contrast. In such cases, 
magnetic resonance (MR) venography without gadolinium, using time-of-flight 
protocol, may yield equally good results and help plan the procedure. Gadolinium 
should be avoided in patients with eGFR of <30 ml/min due to risk of nephrogenic 
systemic fibrosis.
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Once the procedure of angiography is decided, one needs to be ready with 
proper hardware, including various types of wires (0.35 and 0.14 regular and 
double length wires, hydrophilic wires, and stiff wires), various types of diagnostic 
and guiding catheters, larger-size high-pressure balloons, stents, or stent grafts. 
One may need large length vascular sheaths to provide stability to the catheter and 
guide wire, especially when femoral venous access is used.
10.1 How are the target lesion approached?
The indications to perform central vein angioplasty are either the patient is 
symptomatic with functioning vascular access in the upper limb, or the patient has 
had multiple vascular access failures in upper limb, and no reliable long-term vascu-
lar access is available. In such cases, the aim of central vein angioplasty is to create a 
passage to insert central dialysis catheter, which can be either TCC or hybrid graft if 
a reliable arterial inflow is available.
If the target lesion is right brachiocephalic vein or SVC, the right IJV is punctured, 
lesion attempted to be crossed with 0.014′ hydrophilic wire. If that is not successful, 
the right femoral vein is punctured and the lesion approached. The combination of 
this approach from either side helps take simultaneous angiographic shoots to define 
site and extent of lesion in terms of its length and diameter. We have encountered 
several cases, in which the thinnest of wires, sometimes even the coronary wires, 
or CTO wires (chronic thrombotic occlusion) fail to cross the lesion. In such cases, 
recanalization is attempted, which is described as sharp needle recanalization. When 
traditional endovascular methods fail, experienced interventionalists may utilize 
sharp or radiofrequency (RF)-assisted recanalization techniques. Sharp recanaliza-
tion techniques require the use of the back end of a wire, 20- to 22-gauge (15–20 cm) 
percutaneous or transseptal needles, or transjugular intrahepatic portosystemic 
shunt needles [17]. In the absence of any other alternatives, we have been doing it 
with a long Chiba needle. One has to have simultaneous projections in anterior-
posterior and lateral views to be sure that the puncture is in the proper venous 
plain and perforation is avoided. There is no true vessel wall, and a stent is placed to 
reconstitute the vessel wall if this is being done for upper extremity vascular access 
preservation. Otherwise, a catheter is inserted after balloon angioplasty of target 
lesion and creating enough venous diameters to allow smooth passage of the dialysis 
catheter. Recently, a new device called Surfacer® Inside-Out® access catheter system 
is available. The Surfacer Device offers a new approach for repeated venous access in 
patients with thoracic central venous occlusion (TCVOs) that enables the avoidance 
of left-sided catheter placement in individuals awaiting creation or maturation of 
permanent AV access or in patients who have exhausted all thoracic venous access 
options [18]. The author has no personal experience of using it; however, it is meant 
to restore and preserve access in the chronically occluded veins. Its advantages 
include restoration and sustenance of access, reliable and repeatable central venous 
access to the right IJV, preserving viability of secondary central veins, and optimiza-
tion of the placement and maturation of permanent AV access.
TCVO [19], the authors divided TCVO as type 1, defined as any unilateral obstruc-
tion affecting either the internal jugular or subclavian vein. Type 2 includes all cases 
with ipsilateral occlusion of the brachiocephalic vein or ipsilateral obstruction of both 
internal jugular and subclavian veins. In TCVO type 3, both brachiocephalic veins 
are obstructed. Type 4 is characterized by central obstruction of the SVC. Thirty-
six patients with TCVO treated in Vienna, Austria; Oxford, England; or Cologne, 
Germany, who required hemodialysis access between July 2016 and June 2018, with 
TCVO and history of multiple CVCs and AVF, were referred to the participating 
centers for vascular access. Thirty-two (89%) patients were eligible for the inside-out 
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approach (IOA) approach. Thirty-nine treatments were performed, with seven 
patients undergoing the IOA procedure for the second time more than 3 months after 
initial CVC placement. Dialysis access was established successfully in 38 of 39 (97%) 
implementations of the IOA procedure. Median intervention time was 43 minutes. No 
complications occurred. This appears to be a promising method, although this was an 
observational study and no comparison was made to any other methods.
If CVS is bypassed, and adequate inflow with axillary artery is available, the 
HeRO® device can be implanted, which will avoid the need for external TCC and 
minimize risk of CRBSI.
a. If the target lesion is in the subclavian vein or cephalic arch or left brachio-
cephalic vein, approach from arm cephalic, basilic, or rarely brachial vein is 
required, usually combined with femoral vein approach. In cases of tight CTO, 
to provide adequate support and stability to the procedure of angioplasty, 
the wire from the arm vein is passed all the way down to the femoral vein and 
snared out. The hydrophilic wire is then changed over to a stiff wire, and the 
procedure of angioplasty is completed.
b. If attempting to put femoral vein or inferior vena cava (IVC) TCC and dealing 
with iliac vein or IVC stenosis, approach will be from the femoral vein, and 
again recanalization is attempted with thin wire or sharp needle.
PTA with balloon dilatation is the primary basis for endovascular therapy. If 
symptoms are present, PTA is performed; however, patency is poor, so repeat proce-
dures are often required. If it is a first PTA and there is no elastic recoil of the vein on 
table, one should not consider stenting. Recent studies using intravascular ultra-
sound (IVUS) for CVS showed that, although the lesion was sufficiently enlarged on 
angiography after PTA, IVUS demonstrated insufficient dilation or extrusion by the 
balloon catheter [20]. In such cases, repeat angioplasty with larger-size and higher-
pressure balloons can be tried, keeping in mind the risk of central venous rupture. 
Insertion of stents in such situation can be tried. However, numerous studies 
showed failure of stent use, especially in HD VA, because of neointimal hyperplasia 
within the stent, leading to a lower patency rate than that of PTA [21, 22].
The stent graft (SG) is a structure that applies graft material to the inside or 
outside of the stent to create a physical barrier to NIH. Various studies and author’s 
experience have been that even the SGs do not provide long-term venous patency. 
There have been reports of using drug-coated balloons for CVS; however, at pres-
ent, the benefit seems limited.
Stenting for TCVO is appropriate in the following situations, provided there 
are associated hemodynamic or clinical abnormalities: acute elastic recoil (>50%) 
following PTA and recurrent stenosis within a 3-month period of PTA. If balloon 
angioplasty achieves insufficient dilation (e.g., severe recoil) or leads to dissection 
or acute occlusion of the affected vein, bailout stenting is performed. [15]. Balloon 
angioplasty is a basic treatment for central venous lesion, but stent implantation 
is sometimes required. The self-expandable or balloon-expandable stent is chosen 
by the lesion location and characteristics. The lesion in SCV is generally treated by 
self-expandable stent, and right BCV is treated by balloon-expandable stent. The 
organic lesion of innominate vein with plaque is treated by self-expandable stent. 
Note that the innominate venous stenosis is sometimes caused by compression 
between the right brachiocephalic artery and the sternum and this lesion is treated 
by balloon-expandable stent because the radial force of balloon-expandable stent 
is stronger than self-expandable stent. It is important to understand the indication 
and stent selection for central venous PTA [15].
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It is also important to remember to choose a proper-sized stent. This is some-
times not possible to judge from the angiographic images, and what appears to be 
adequate angioplasty could be inadequate in terms of adequate vein diameter. IVUS 
is sometimes useful to guide the choice of proper balloon or stent size, as what 
appears to be an adequately treated vein could be having significant underlying 
stenosis, which is not possible to realize on conventional two-dimensional angiogra-
phy. IVUS is an invasive modality that provides cross-sectional imaging of the veins 
but without the need for ionizing radiation or contrast administration. In addition 
to being a diagnostic tool that is easy and repeatable, it aids treatment decision-
making. Though IVUS may be better suited than traditional venography to identify 
intraluminal narrowing and pre-/post-intervention outcomes, additional study is 
warranted to better characterize the value of IVUS in the VA-related CVS patient 
population. In a patient with CVS and prior allergy to iodinated contrast, angiog-
raphy was performed using 1 cc of contrast, CVS confirmed, and the rest of the 
procedure of angioplasty and confirmation of adequate result was completed using 
IVUS (personal communication, Dr. Daniel Patel, Interventional Nephrologist, 
Volusia-Flagler Vascular Centre, Daytona Beach, Florida, USA).
If CRS is the cause for catheter malfunction, the same can be confirmed during 
catheter exchange procedure by doing pullback angiography prior to full removal 
of TCC. There can be only CRS, which can be tackled by balloon angioplasty and 
fibrin sheath disruption. Rarely (and in the authors’ own experience), the CRS can 
be snared out. However, the CRS can be associated with CRAT. And it can become 
tricky to perform angioplasty, as the risk of pulmonary thromboembolism due 
to large CRAT, attached to TCC tip, is high. Sometimes, CRAT is attached to the 
wall of the right atrium. In such a case, if TCC is functioning well, the patient can 
be anticoagulated and kept under close observation. For a large CRAT or infected 
CRAT, attached to TCC tip, and where it is risky and not advisable to remove the 
CRAT, AngioVac thrombectomy device can be used. If these patients are poor can-
didates for conventional therapy of thrombolytics or surgical thromboembolectomy 
because of bleeding, failure of thrombolytics, or hemodynamic instability, they 
may benefit from percutaneous mechanical thrombectomy by AngioVac, which is 
proved to be effective for complete evacuation in most patients [23].
Surgical options may be considered for CVS, when the stenosis persists, and 
there are no alternative avenues to provide long-term reliable VA. One must assess 
the AVF for flow velocity, as this may be the cause of CVD. In such cases, inflow 
reduction either surgically or percutaneously can be performed. Another surgical 
option is unusual bypass including reconstruction surgery and claviculectomy or 
first rib resection if there is thoracic outlet syndrome. If an experienced vascular 
surgeon is available, the bypass surgery can be performed using graft (PTFE) from 
the brachial artery to ipsilateral or contralateral internal jugular veins or axillary or 
femoral veins. Direct connection to SVC or right atrium have also been attempted. 
One must remember that such surgeries are complicated and carries its own risks 
and complications.
There are occasions when there is coexistence of CVS and stenosis in the drain-
ing vein, either juxta-anastomotic or away from the site of anastomosis. In such 
situation, one must attempt and achieve patency of CVS lesion. Failure to do so can 
lead to severe swelling of the ipsilateral arm. The best way to relieve symptomatic 
CVS is closure of AVF. But it is not possible in patients, who have the last surviving 
access and shortage of vascular estate.
But, sometimes, there are more than one possible approach to a problem, 
and the opinion varies as per the specialist handling the case. For example, refer 
to Figure 4, a middle-aged lady on hemodialysis with CVS who had undergone 
angioplasty with stenting and resolution of right upper limb painful edema. She 
11
Hemodialysis Vascular Access with Central Venous Disease
DOI: http://dx.doi.org/10.5772/intechopen.93030
presented with the same symptoms 6 months later. The angiography image shows 
in-stent stenosis. It was difficult to negotiate the stenosis. Various opinions were 
sought. The interventional nephrologist found that it was the high-flow fistula 
(flow volume 2600 ml/min, very high) which was responsible for her symptoms, 
and the patient should undergo flow reduction procedure. The interventional 
radiologist said that attempt to do in-stent angioplasty, followed by stent placement 
within the stent, should be the first option. The vascular access surgeon said that 
the stenosis is due to external compression and the patient should undergo middle 
1/3rd claviculectomy to relieve her symptoms.
11. Cardiovascular consequences of AVF
Sometimes very-high-flow AVFs can lead to VH, progressive aneurysmal dilata-
tion of vein with skin ulceration, hemodialysis access-induced distal ischemia, and 
high-output heart failure with or without pulmonary hypertension. AVFs have 
effects on cardiac functions related to the increase in preload and cardiac output 
(CO). It is difficult to define cardiovascular consequences due to AVF in a precise 
manner. This is due to the fact that patients requiring long-term hemodialysis tend 
to have volume overload due to water and salt retention. There could also be pres-
sure load due to arterial sclerosis and hypertension and increased CO secondary to 
chronic anemia. In addition, many hemodialysis patients have significant pre-exist-
ing myocardial, valvular, or coronary heart disease, as the vascular calcification due 
to CKD-MBD (chronic kidney disease—mineral and bone disorder). Congestive 
heart failure (CHF) is highly prevalent among patients with ESRD. Approximately 
35–40% of patients with ESRD have an established CHF diagnosis at initiation of 
hemodialysis. Worsening in cardiac functions soon after AVF creation has also been 
observed favoring a causative effect of the AVF on certain cardiac functions [24].
12. Conclusion
CVD is a common occurrence in HD patients, either due to mechanical or 
hemodynamic factors. It could be related to catheters or AVF. It can be symptomatic 
or asymptomatic. Interventions will be required in symptomatic patients and in 
those who have VA malfunction. There are various options, and one needs to choose 
the modality based on the patient’s need. The outcomes cannot be predicted as each 
vein behaves differently. Proper knowledge of anatomical lesion, pathophysiology 
of the lesion, patient needs, and expertise available will determine the intervention 
Figure 4. 
Right SCV in-stent thrombosis.
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modality and outcomes. There is a need for multidisciplinary approach to tackle the 
situation. We, at our institute, work with a motto which is slightly modified from 
the old proverb, and we proudly say that “if there’s a will and a vein, there’s a way.” 
Prevention of CVS by catheter avoidance is an ideal situation; however CVD due to 
hemodynamic issues not related to catheters cannot be avoided, and VA surveillance 
is the best way for early diagnosis and management of such lesions.
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